Effectiveness and Safety of Apixaban, Dabigatran and Rivaroxaban versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation: ARISTOPHANES Subgroup Analysis

Friday, October 11, 2019, 10:15 – 11:15 AM, 2:25 - 3:25 PM
Saturday, October 12, 2019, 10:00 – 11:00 AM, 2:15 - 3:15 PM

Deitelzweig S¹, Keshishian A²,³, Kang A⁴, Dhamane A⁴, Luo X⁵, Li X⁴, Balachander N⁴, Rosenblatt L⁴, Mardekian J⁶, Pan X⁴, Di Fusco M⁶, Garcia AB⁴,⁷, Yuce H³, Lip GYH⁸

1. Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, LA, USA and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; 2. STATinMED Research, Ann Arbor, MI; 3. New York City College of Technology, City University of New York, New York, NY; 4. Bristol-Myers Squibb Company, Lawrenceville, NJ; 5. Pfizer, Inc., Groton, CT; 6. Pfizer, Inc., New York, NY; 7. University of North Carolina, Chapel Hill, NC; 8. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Purpose
The prevalence of obesity in nonvalvular atrial fibrillation (NVAF) patients is apparent in trials and real-world studies; however, there is limited data on the effectiveness and safety of anticoagulation specific to this population. This study evaluated stroke/systemic embolism (SE) and major bleeding (MB) among obese NVAF patients using non-VKA oral anticoagulants (NOACs) vs warfarin in the ARISTOPHANES (Anticoagulants for Reduction In STroke: Observational Pooled analysis on Health outcomes ANd Experience of patientS) study population.

Methods
A retrospective study of obese (identified using diagnosis codes) NVAF patients initiating apixaban, dabigatran, rivaroxaban, or warfarin from 01JAN2013-30SEP2015 was conducted pooling CMS Medicare data and 4 US commercial claims databases, covering >180 million beneficiaries annually (~56% of the US population). Propensity score matching (PSM) was used to balance baseline characteristics between patients prescribed each NOAC and warfarin. Cox models were used to evaluate the relative risk of stroke/SE and MB.

Results
PSM pairs had 6-8 months of follow-up. Apixaban had lower rates of MB while dabigatran and rivaroxaban had similar rates of MB vs warfarin. All NOACs showed similar rates of stroke/SE vs warfarin.

Conclusions
Among obese NVAF patients, all NOACs had similar stroke/SE rates vs warfarin; MB rate was lower for apixaban and not significantly different for dabigatran or rivaroxaban vs warfarin.
2019 SCIENTIFIC POSTER SESSION